文献速递复苏、休克与脓毒症创伤与烧伤

Toll样受体4参与创伤/失血性休克后血管加压反应下降

Involvement of Toll-Like Receptor 4 in Decreased Vasopressor Response Following Trauma/Hemorrhagic Shock.
PubMed 文献 · Crit Care Explor · 2021-07-06
一句话结论动物实验显示创伤/失血性休克后TLR4激活使血管平滑肌α1肾上腺素能受体共内化,导致对去氧肾上腺素反应下降,抑制TLR4可改善血压。

该研究在大鼠创伤/失血性休克模型中探讨血管加压反应下降的机制。研究采用剖腹术+平均动脉压40 mmHg持续90分钟+乳酸林格液复苏2小时的模型,使用resatorvid(TAK-242)和resveratrol抑制TLR4,并将平滑肌细胞与LPS(10 ng/mL)或休克血浆孵育。结果显示休克血浆激活平滑肌细胞TLR4/NF-κB通路,TLR4与α1肾上腺素能受体在细胞膜共定位并发生共内化,钙内流受损;敲除或抑制TLR4后钙内流恢复、血压改善。

要点

  • 大鼠创伤/失血性休克模型(剖腹术+MAP 40 mmHg 90分钟+乳酸林格液复苏2小时)出现对去氧肾上腺素反应下降。
  • 抑制TLR4(resatorvid/TAK-242、resveratrol)可改善创伤/失血性休克大鼠的血压。
  • 休克血浆激活平滑肌细胞TLR4/NF-κB通路,TLR4与α1肾上腺素能受体共定位于细胞膜并发生共内化。
  • TLR4激活导致α1肾上腺素能受体膜水平降低,钙内流受损;敲除或抑制TLR4后钙内流恢复。
  • 该机制为动物实验发现,尚未在临床验证,不能据此改变目前血管加压药使用策略。

适用人群与场景

  • 实验对象为Wistar大鼠,采用剖腹术联合平均动脉压40 mm Hg持续90分钟、随后乳酸林格液复苏2小时的创伤/失血性休克模型;不涉及人类患者。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型为动物实验(Wistar大鼠创伤/失血性休克模型),非临床研究,无样本量、中心数及临床终点。
  • 创伤/失血性休克导致对去氧肾上腺素反应下降,而抑制TLR4(resatorvid/TAK-242、resveratrol)改善血压。
  • 创伤/失血性休克血浆激活平滑肌细胞TLR4/NF-κB通路。
  • TLR4与α1肾上腺素能受体在细胞膜共定位,TLR4激活引起两者共内化。
  • 与创伤/失血性休克血浆孵育的细胞钙内流受损,敲除或抑制TLR4后恢复。
  • 结论:TLR4激活通过降低膜α1肾上腺素能受体水平使血管平滑肌细胞对血管加压药脱敏。

证据类型、等级与局限

  • 证据类型为动物实验(大鼠模型及细胞实验),非RCT、队列或系统评价;原文未给出证据等级或推荐强度。
  • 局限:仅动物与细胞水平,未在人类验证;具体样本量原文未提及;不能直接外推至临床决策。

对床旁实践的改变

  • 该内容为机制性动物实验,暂不能改变急诊/ICU对创伤/失血性休克患者血管加压药的选择、剂量或时机。
  • 提示TLR4激活可能参与休克后血管对儿茶酚胺反应下降,但尚无临床干预数据,不推荐据此使用resatorvid或resveratrol。
  • 适用人群:仅限实验大鼠模型;不适用于临床患者。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

UNLABELLED: Refractory vascular failure due to the inability of vascular smooth muscle to respond to vasoconstrictors such as phenylephrine is a final common pathway for severe circulatory shock of any cause, including trauma/hemorrhagic shock. Increased inflammation, Toll-like receptor 4 activation, and decreased response of the alpha-1 adrenergic receptors which control vascular tone have been reported in trauma/hemorrhagic shock.

HYPOTHESIS: In trauma/hemorrhagic shock, Toll-like receptor 4 activation contributes to vascular failure via decreased bioavailability of adrenergic receptors.

DESIGN AND MEASUREMENTS: Trauma/hemorrhagic shock was induced in Wistar rats (laparotomy combined with mean arterial pressure at 40 mm Hg for 90 min followed by 2 hr resuscitation with Lactated Ringers solution). To inhibit Toll-like receptor 4, resatorvid (TAK-242) and resveratrol were used, and plasma was collected. Smooth muscle cells were incubated with lipopolysaccharide (10 ng/mL) or plasma. Inflammatory cytokines were screened using dot-blot. Toll-like receptor 4 and nuclear factor κB activation and cellular localization of the alpha-1 adrenergic receptor were measured by immunofluorescence imaging and Western blot analysis. Clustered regularly interspaced short palindromic repeats/Cas9 was used to knock out Toll-like receptor 4, and calcium influx following stimulation with phenylephrine was recorded.

MAIN RESULTS: Trauma/hemorrhagic shock caused a decreased response to phenylephrine, whereas Toll-like receptor 4 inhibition improved blood pressure. Trauma/hemorrhagic shock plasma activated the Toll-like receptor 4/nuclear factor κB pathway in smooth muscle cells. Double labeling of Toll-like receptor 4 and the alpha-1 adrenergic receptor showed that these receptors are colocalized on the cell membrane. Activation of Toll-like receptor 4 caused cointernalization of both receptors. Calcium influx was impaired in cells incubated with trauma/hemorrhagic shock plasma but restored when Toll-like receptor 4 was knocked out or inhibited.

CONCLUSIONS: Activation of the Toll-like receptor 4 desensitizes vascular smooth muscle cells to vasopressors in experimental trauma/hemorrhagic shock by reducing the levels of membrane alpha-1 adrenergic receptor.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Mazor R, Dos Santos F, Li JB, et al. Involvement of Toll-Like Receptor 4 in Decreased Vasopressor Response Following Trauma/Hemorrhagic Shock. Crit Care Explor. 2021. PMID: 34250499. doi:10.1097/CCE.0000000000000469

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。